developing novel therapeutics called fatty acid synthase (FASN) inhibitors to treat important diseases such as non-alcoholic steatohepatitis (NASH), acne and various cancers.
Our focus and expertise in fatty acid synthase enables us to break new ground in targeting the dysfunctional metabolic pathways driving these diseases.
Stage of Development
Therapeutic area
Indication
Preclinical
Phase 1
Phase 2
Phase 3
* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China
Stage of Development
Therapeutic area
Indication
Expected milestone
Preclinical
Phase 1
Phase 2
Phase 3
** Moderate to advanced fibrosis
** Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China
Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at week 26 compared to 18% placebo (p<0.001)
San Mateo, Calif., June 7, 2023 – Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the
Denifanstat Showed Statistically Significant Improvements Across Key Disease Markers in FASCINATE-2 Study After 26 Weeks of Treatment Highlights to be Included in Oral Presentation Session at The Liver Meeting on
© 2023 Sagimet Biosciences. All Rights Reserved. Privacy Policy | Terms of Use Agreement
